Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | Director | September 15, 2026 | September 15, 2026 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP Finance CFO | February 02, 2024 | February 06, 2024 |
| Zymeworks Inc.ZYME · Entity 4458 | Director | January 12, 2026 | January 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date September 15, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,184 |
Reported balance
After 2026-09-15 transaction · row 1
1 source rowRow 1 · 2026-09-15 · Sale · Disposed 1,000 · Balance 8,184 |
REGENERON PHARMACEUTICALS, INC.
Report date February 02, 2024 · Filed February 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,693 |
Ending reported balance
After 2024-02-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-02-02 · Exercise / conversion · Acquired 400 · Balance 23,974 Row 2 · 2024-02-02 · Tax withholding · Disposed 281 · Balance 23,693 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $378.98 · Expires 2027-12-12 | Direct | 11,787 |
Reported balance
After 2024-02-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-02 · Exercise / conversion · Disposed 400 · Balance 11,787 F1: The stock option award vests in four equal annual installments, commencing one year after the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 270 |
Reported balance
Holding disclosure · report date 2024-02-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 270 |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option award vests in four equal annual installments, commencing one year after the date of grant.
Zymeworks Inc.
Report date January 12, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.16 · Expires 2036-01-11 | Direct | 11,500 |
Reported balance
After 2026-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-12 · Grant · Acquired 11,500 · Balance 11,500 F1: Stock options vest on January 12, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2027-01-12 | Direct | 7,700 |
Reported balance
After 2026-01-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-12 · Grant · Acquired 7,700 · Balance 7,700 F2: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F3: RSUs vest on January 12, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest on January 12, 2027.
F2: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
F3: RSUs vest on January 12, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2020 Filed Jun 12, 2020 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 31 | $616.00 | $19,096.00 |
DisclosureSEC source: 0001708138-20-000071 · edgardoc.xml · nonDerivative · entry 9 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,572 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 34 | $614.41 | $20,889.94 |
DisclosureSEC source: 0001708138-20-000071 · edgardoc.xml · nonDerivative · entry 8 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,603 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 23 | $613.53 | $14,111.19 |
DisclosureSEC source: 0001708138-20-000071 · edgardoc.xml · nonDerivative · entry 7 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,637 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 177 | $612.74 | $108,454.98 |
DisclosureSEC source: 0001708138-20-000071 · edgardoc.xml · nonDerivative · entry 6 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,660 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 177 shares of Company stock on June 11, 2020 at prices ranging from $612.26 to $612.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 11, 2020 at each separate price. Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 14 | $611.82 | $8,565.48 |
DisclosureSEC source: 0001708138-20-000071 · edgardoc.xml · nonDerivative · entry 5 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,837 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 65 | $608.91 | $39,579.15 |
DisclosureSEC source: 0001708138-20-000071 · edgardoc.xml · nonDerivative · entry 4 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,851 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 445 | $607.50 | $270,337.50 |
DisclosureSEC source: 0001708138-20-000071 · edgardoc.xml · nonDerivative · entry 3 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,916 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $272.70 | $0.00 |
DisclosureSEC source: 0001708138-20-000071 · edgardoc.xml · derivative · entry 15 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,500 shares Expires 2023-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 2,512 | $610.18 | $1,532,772.16 |
DisclosureSEC source: 0001708138-20-000071 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,361 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,500 | $272.70 | $954,450.00 |
DisclosureSEC source: 0001708138-20-000071 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,873 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 527 | $610.25 | $321,601.75 |
DisclosureSEC source: 0001708138-20-000068 · edgardoc.xml · nonDerivative · entry 21 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,373 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 527 shares of Company stock on June 9, 2020 at prices ranging from $610.00 to $610.54. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 9, 2020 at each separate price. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 681 | $609.53 | $415,089.93 |
DisclosureSEC source: 0001708138-20-000068 · edgardoc.xml · nonDerivative · entry 20 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,900 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 681 shares of Company stock on June 9, 2020 at prices ranging from $609.41 to $609.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 9, 2020 at each separate price. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,511 | $608.50 | $919,443.50 |
DisclosureSEC source: 0001708138-20-000068 · edgardoc.xml · nonDerivative · entry 19 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,581 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 1,511 shares of Company stock on June 9, 2020 at prices ranging from $608.14 to $608.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 9, 2020 at each separate price. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 619 | $607.47 | $376,023.93 |
DisclosureSEC source: 0001708138-20-000068 · edgardoc.xml · nonDerivative · entry 18 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,092 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 619 shares of Company stock on June 9, 2020 at prices ranging from $607.00 to $607.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 9, 2020 at each separate price. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 353 | $606.79 | $214,196.87 |
DisclosureSEC source: 0001708138-20-000068 · edgardoc.xml · nonDerivative · entry 17 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,711 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 353 shares of Company stock on June 9, 2020 at prices ranging from $606.46 to $606.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 9, 2020 at each separate price. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 289 | $605.14 | $174,885.46 |
DisclosureSEC source: 0001708138-20-000068 · edgardoc.xml · nonDerivative · entry 16 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,064 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 289 shares of Company stock on June 9, 2020 at prices ranging from $605.07 to $605.63. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 9, 2020 at each separate price. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 50 | $604.14 | $30,207.00 |
DisclosureSEC source: 0001708138-20-000068 · edgardoc.xml · nonDerivative · entry 15 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,353 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 131 | $603.68 | $79,082.08 |
DisclosureSEC source: 0001708138-20-000068 · edgardoc.xml · nonDerivative · entry 14 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,403 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 131 shares of Company stock on June 9, 2020 at prices ranging from $603.33 to $603.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 9, 2020 at each separate price. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 110 | $602.38 | $66,261.80 |
DisclosureSEC source: 0001708138-20-000068 · edgardoc.xml · nonDerivative · entry 13 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,534 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 110 shares of Company stock on June 9, 2020 at prices ranging from $602.35 to $602.41. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 9, 2020 at each separate price. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $272.70 | $0.00 |
DisclosureSEC source: 0001708138-20-000068 · edgardoc.xml · derivative · entry 28 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock · 1,500 shares Expires 2023-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,250 | $0.00 Strike: $272.70 | $0.00 |
DisclosureSEC source: 0001708138-20-000068 · edgardoc.xml · derivative · entry 27 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 2,250 shares Expires 2023-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,250 | $0.00 Strike: $272.70 | $0.00 |
DisclosureSEC source: 0001708138-20-000068 · edgardoc.xml · derivative · entry 26 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,250 Underlying: Common Stock · 2,250 shares Expires 2023-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $272.70 | $0.00 |
DisclosureSEC source: 0001708138-20-000068 · edgardoc.xml · derivative · entry 25 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 2,500 shares Expires 2023-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $272.70 | $0.00 |
DisclosureSEC source: 0001708138-20-000068 · edgardoc.xml · derivative · entry 24 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 3,500 shares Expires 2023-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $272.70 | $0.00 |
DisclosureSEC source: 0001708138-20-000068 · edgardoc.xml · derivative · entry 23 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 3,500 shares Expires 2023-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,086 | $592.43 | $643,378.98 |
DisclosureSEC source: 0001708138-20-000068 · edgardoc.xml · nonDerivative · entry 12 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,644 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,500 | $272.70 | $409,050.00 |
DisclosureSEC source: 0001708138-20-000068 · edgardoc.xml · nonDerivative · entry 11 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,630 | $592.43 | $965,660.90 |
DisclosureSEC source: 0001708138-20-000068 · edgardoc.xml · nonDerivative · entry 10 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,230 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,250 | $272.70 | $613,575.00 |
DisclosureSEC source: 0001708138-20-000068 · edgardoc.xml · nonDerivative · entry 9 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,630 | $592.43 | $965,660.90 |
DisclosureSEC source: 0001708138-20-000068 · edgardoc.xml · nonDerivative · entry 8 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,610 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,250 | $272.70 | $613,575.00 |
DisclosureSEC source: 0001708138-20-000068 · edgardoc.xml · nonDerivative · entry 7 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,240 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,811 | $592.40 | $1,072,836.40 |
DisclosureSEC source: 0001708138-20-000068 · edgardoc.xml · nonDerivative · entry 6 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,990 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,500 | $272.70 | $681,750.00 |
DisclosureSEC source: 0001708138-20-000068 · edgardoc.xml · nonDerivative · entry 5 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 2,536 | $592.43 | $1,502,402.48 |
DisclosureSEC source: 0001708138-20-000068 · edgardoc.xml · nonDerivative · entry 4 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,301 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,500 | $272.70 | $954,450.00 |
DisclosureSEC source: 0001708138-20-000068 · edgardoc.xml · nonDerivative · entry 3 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 2,536 | $592.43 | $1,502,402.48 |
DisclosureSEC source: 0001708138-20-000068 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,337 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,500 | $272.70 | $954,450.00 |
DisclosureSEC source: 0001708138-20-000068 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,873 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 23:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 320 | $573.40 | $183,488.00 |
DisclosureSEC source: 0001708138-20-000044 · edgardoc.xml · nonDerivative · entry 29 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,373 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F14 · price: Represents volume-weighted average price of sales of 320 shares of Company stock on April 20, 2020 at prices ranging from $573.01 to $573.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 23:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 64 | $572.42 | $36,634.88 |
DisclosureSEC source: 0001708138-20-000044 · edgardoc.xml · nonDerivative · entry 28 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,693 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F13 · price: Represents volume-weighted average price of sales of 64 shares of Company stock on April 20, 2020 at prices ranging from $572.19 to $572.48. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 23:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 114 | $571.65 | $65,168.10 |
DisclosureSEC source: 0001708138-20-000044 · edgardoc.xml · nonDerivative · entry 27 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,757 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 23:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 66 | $569.22 | $37,568.52 |
DisclosureSEC source: 0001708138-20-000044 · edgardoc.xml · nonDerivative · entry 26 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,871 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 66 shares of Company stock on April 20, 2020 at prices ranging from $569.10 to $569.33. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 23:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 126 | $568.11 | $71,581.86 |
DisclosureSEC source: 0001708138-20-000044 · edgardoc.xml · nonDerivative · entry 25 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,937 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 126 shares of Company stock on April 20, 2020 at prices ranging from $568.10 to $568.17. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 23:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 114 | $567.76 | $64,724.64 |
DisclosureSEC source: 0001708138-20-000044 · edgardoc.xml · nonDerivative · entry 24 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,063 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 23:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 944 | $566.44 | $534,719.36 |
DisclosureSEC source: 0001708138-20-000044 · edgardoc.xml · nonDerivative · entry 23 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,177 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 944 shares of Company stock on April 20, 2020 at prices ranging from $566.01 to $566.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 23:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 902 | $565.52 | $510,099.04 |
DisclosureSEC source: 0001708138-20-000044 · edgardoc.xml · nonDerivative · entry 22 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,121 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 902 shares of Company stock on April 20, 2020 at prices ranging from $565.05 to $565.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 23:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 340 | $564.76 | $192,018.40 |
DisclosureSEC source: 0001708138-20-000044 · edgardoc.xml · nonDerivative · entry 21 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,023 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 340 shares of Company stock on April 20, 2020 at prices ranging from $564.14 to $564.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 23:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 225 | $563.74 | $126,841.50 |
DisclosureSEC source: 0001708138-20-000044 · edgardoc.xml · nonDerivative · entry 20 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,363 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 225 shares of Company stock on April 20, 2020 at prices ranging from $563.56 to $563.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 23:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 35 | $562.71 | $19,694.85 |
DisclosureSEC source: 0001708138-20-000044 · edgardoc.xml · nonDerivative · entry 19 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,588 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 23:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $272.70 | $0.00 |
DisclosureSEC source: 0001708138-20-000044 · edgardoc.xml · derivative · entry 32 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 12,500 shares Expires 2023-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F15 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 23:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 9,250 | $555.82 | $5,141,335.00 |
DisclosureSEC source: 0001708138-20-000044 · edgardoc.xml · nonDerivative · entry 18 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,623 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.